Mitochondrial health and aging are deeply connected: as mitochondria lose function with age, so does cellular energy production, metabolic regulation, and stress resilience. At TelosRX, longevity-focused protocols — subject to provider evaluation — are designed with this cellular biology in mind.
This research review examines what current evidence says about mitochondrial aging, including the role of NAD+, the emerging science of mitochondria-derived peptides such as MOTS-c, and the intervention with the strongest supporting data in humans: exercise.
Finding 1: NAD+ Declines Sharply With Age
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme that sits at the center of mitochondrial energy metabolism. Every cell in the body uses NAD+ to convert nutrients into ATP through the electron transport chain. It also activates sirtuins — enzymes involved in DNA repair, inflammation control, and gene expression regulation.
Research consistently shows that NAD+ levels drop by roughly 50% between young adulthood and middle age, and continue declining thereafter. The mechanisms driving this decline include:
- Reduced synthesis from tryptophan via the kynurenine pathway
- Increased consumption by PARP enzymes, which activate in response to accumulating DNA damage
- Upregulation of CD38, an NAD-consuming enzyme that increases sharply with age-related inflammation
A 2025 review published in PMC summarizes the current understanding of NAD+ biology and the evidence base for supplementation as a mitochondrial support strategy.
Finding 2: NAD+ Precursors Show Preclinical Promise
Two NAD+ precursors have attracted the most research attention: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both can raise NAD+ levels in human trials, but the clinical significance of this increase — in terms of measurable health outcomes — remains an active area of investigation.
| Precursor | Conversion Pathway | Key Research Finding | Current Evidence Level |
|---|---|---|---|
| NMN | Cellular uptake via Slc12a8 transporter → NMNAT enzymes → NAD+ | Raised blood NAD+ in human trials; improved insulin sensitivity in one small RCT in postmenopausal women | Preliminary (small RCTs only) |
| NR | NRK1/NRK2 enzymes → NMN → NAD+ | Consistently raises blood NAD+ across multiple human studies; limited functional outcome data | Preliminary (small RCTs only) |
Most published human studies on NMN and NR are small (under 100 participants) and short-duration (under 12 weeks). Larger, longer trials are underway. Current evidence does not support strong clinical recommendations for either precursor as a standalone anti-aging intervention. See the TelosRX NMN vs. NR comparison guide for a detailed breakdown of the differences.
Finding 3: Mitophagy Efficiency Declines With Age
Mitophagy is the cellular quality control process by which damaged or dysfunctional mitochondria are identified, sequestered, and recycled. It is, in essence, the cell's dedicated garbage collection system for mitochondria.
With aging, mitophagy efficiency declines due to several converging factors:
- Reduced expression of PINK1 and Parkin proteins, which tag damaged mitochondria for removal
- Decreased autophagosome formation, reducing the capacity to clear tagged organelles
- Accumulation of damaged mitochondria that release reactive oxygen species (ROS), creating a feedback loop that further impairs mitophagy
The result is a progressive accumulation of dysfunctional mitochondria that produce less ATP and more cellular stress signals. This process is increasingly recognized as a central driver of age-related metabolic decline, not merely a downstream consequence of it.
Finding 4: MOTS-c Is an Emerging Area of Mitochondrial Peptide Research
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a peptide encoded within the mitochondrial genome itself — an unusual feature, since most mitochondrial proteins are encoded by nuclear DNA. Identified in 2015, it has since become an active focus of metabolic aging research.
Preclinical research in rodent models has explored its potential role in:
- Improving insulin sensitivity and glucose uptake in skeletal muscle
- Modulating the cellular and metabolic response to exercise
- Extending lifespan in mouse models under certain dietary and stress conditions
Human research on MOTS-c is at an early stage. No clinical recommendations can be drawn from available preclinical data, and compounded MOTS-c preparations are not FDA-approved. For a research summary, see the TelosRX MOTS-c Metabolic Research guide.
Finding 5: Exercise Remains the Most Evidence-Backed Mitochondrial Intervention
Of all proposed strategies to support mitochondrial health, exercise has by far the strongest and most consistent evidence base in humans. The mechanisms are well-characterized:
- Mitochondrial biogenesis: Exercise activates PGC-1alpha, the master regulator of mitochondrial production. More mitochondria per cell means greater ATP-generating capacity and resilience under metabolic stress.
- Improved mitophagy: Regular physical activity upregulates PINK1 and Parkin signaling, improving clearance of damaged mitochondria over time.
- NAD+ recycling: Exercise increases NAMPT enzyme activity — a key rate-limiting step in NAD+ biosynthesis — raising cellular NAD+ independently of supplementation.
A landmark 2017 study in Cell Metabolism (PubMed) compared high-intensity interval training, resistance training, and combined training in young and older adults. HIIT produced the largest increases in mitochondrial capacity across both age groups, with older adults showing particularly pronounced gains in mitochondrial protein synthesis — suggesting that the mitochondrial machinery retains significant adaptive potential even in aging muscle.
Finding 6: NAD+ Infusion and Oral Supplementation as Longevity Protocols
Beyond oral NMN and NR, intravenous NAD+ infusion is offered by some clinics as a strategy to rapidly raise systemic NAD+ levels. The proposed rationale is that IV delivery bypasses gut absorption variability and achieves higher peak plasma concentrations than oral supplementation.
The evidence base for IV NAD+ in longevity applications is limited to case reports and small observational studies. The therapy has a more established track record in addiction medicine, where it is used to support detoxification, but its use for healthy aging and mitochondrial support is investigational.
At TelosRX, NAD+ therapy options — including oral precursor protocols — are evaluated through asynchronous provider review, subject to medical approval by a licensed provider. Compounded NAD+ preparations are not FDA-approved. For context on what an NAD+ telehealth evaluation involves, see the TelosRX NAD+ Therapy guide.
Frequently Asked Questions
What causes mitochondrial decline with aging?
Mitochondrial decline with aging results from accumulated oxidative DNA damage, reduced NAD+ availability, impaired mitophagy, and decreased expression of key mitochondrial biogenesis regulators such as PGC-1alpha.
What is NAD+ and why does it decline with age?
NAD+ is a coenzyme essential for cellular energy metabolism and DNA repair via sirtuins. NAD+ levels decline with age due to decreased biosynthesis, increased consumption by inflammatory enzymes such as CD38 and PARP, and reduced recycling efficiency.
What is the difference between NMN and NR for NAD+ support?
NMN and NR are both NAD+ precursors that convert to NAD+ through different enzymatic pathways. NR converts via NRK enzymes; NMN converts via NMNAT enzymes after cellular uptake. Current clinical evidence is preliminary for both.
What is MOTS-c?
MOTS-c is a mitochondria-derived peptide encoded in the mitochondrial genome. Preclinical research in rodents suggests it may influence insulin sensitivity, exercise capacity, and metabolic rate. Human research is at an early stage and no clinical recommendations can be drawn from available data.
Does exercise actually improve mitochondrial health?
Yes. Exercise, particularly high-intensity interval training, is the most evidence-backed intervention for increasing mitochondrial density and function in humans. A landmark 2017 Cell Metabolism study found that HIIT significantly upregulated mitochondrial biogenesis across both young and older age groups.
Is NAD+ therapy available through TelosRX?
NAD+ therapy options, including oral precursors subject to provider approval, may be evaluated through TelosRX's asynchronous telehealth platform. All protocols are subject to evaluation by a licensed provider; approval is not guaranteed and compounded preparations are not FDA-approved.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.